Recently Approved

August 2006
Pharmaceutical Representative;Aug2006, Vol. 36 Issue 8, p14
The article offers a list of newly approved drugs in the U.S. The Food and Drug Administration (FDA) has approved the new indication for Cubicin by Massachusetts-based Cubist Pharmaceuticals Inc. for the treatment of Staphylococcus aureus bloodstream infections. GlaxoSmithKline's Hycamtin has expanded its indication to include treatment of stage IV-B, recurrent or persistent carcinoma of the cervix by combining it with cisplatin. Valeant Pharmaceuticals International has received marketing clearance for Zelapar.


Related Articles

  • Valeant Pharmaceuticals signs promotion agreement with GlaxoSmithKline.  // PharmaWatch: CNS;Dec2008, Vol. 7 Issue 12, p8 

    The article reports on the agreement between Valeant Pharmaceuticals and GlaxoSmithKline for the promotion of Diastat and Diastat AcuDial, which is an acute at-home medication for patients two years and older on stable antiepileptic medications approved by the U.S. Food and Drug Administration....

  • Nausea Update.  // PharmaWatch: CNS;Jul2006, Vol. 5 Issue 7, p9 

    The article provides updates on drug development for the treatment of nausea in the U.S. BioDelivery Sciences International Inc. has expressed optimism over the approval of its anti-nausea drug Emezine after its meeting with the Food and Drug Administration (FDA). Valeant Pharmaceuticals...

  • New delivery system helps control seizures. Tobias, Lawrence D. // Drug Topics;10/24/2005, Vol. 149 Issue 20, p8 

    This article introduces Diastat AcuDial (diazepam rectal gel), a new gel-based, delivery system containing a common benzodiazepine that may provide a needed safety net for patients with epilepsy who are refractory to traditional mono- and combination pharmacotherapy and who experience bouts of...

  • TAKING CONTROL OF EPILEPSY. Magill-Lewis, Jillene // Drug Topics;3/6/2006, Vol. 150 Issue 5, p30 

    The article focuses on the study conducted that investigates the efficacy of antiepileptic drugs (AED) in improving the lives of people with epilepsy in the U.S. Valeant Pharmaceuticals International is in phase III trials with retigabine to evaluate its effect on epilepsy patients. The company...

  • Valeant's Pipeline Star Potiga Gets FDA Approval for Seizures. Morrison, Trista // BioWorld Today;6/14/2011, Vol. 22 Issue 114, p3 

    The article reports on the approval of the potassium channel opener Potiga as an adjunctive treatment for partial-onset seizures granted by the U.S. Food and Drug Administration (FDA) to Valeant Pharmaceuticals International Inc. and partner GlaxoSmithKline plc. It mentions that Potiga is...

  • Ezogabine: Novel adjunctive antiepileptic drug. Tanzi, Maria G. // Pharmacy Today;Aug2011, Vol. 17 Issue 8, p40 

    The article highlights the approval given by the U.S. Food and Drug Administration (FDA) on ezogabine (Potiga) developed by Valeant Pharmaceuticals International and GlaxoSmithKline. It notes that the drug is an ezogabine indicated as an adjunctive treatment of partial-onset of seizures on...

  • Valeant/GlaxoSmithKline: Potiga's novel mechanism provides hope for drug-resistant epilepsy patients.  // PharmaWatch: CNS;Jul2011, Vol. 10 Issue 7, p4 

    The article highlights the move of the U.S. Food and Drug Administration (FDA) to approve Potiga, a novel drug, jointly marketed by Valeant Pharmaceuticals International Inc. and GlaxoSmithKline. It notes that the drug will provide a useful treatment option for adult patients with drug-resistant...

  • MEDA: Potiga (ezogabine) Receives FDA Approval.  // Biomedical Market Newsletter;6/19/2011, p966 

    The article reports that Valeant Pharmaceuticals International Inc. has been approved by the U.S. Food & Drug Administration (FDA) in June 2011 to market Meda AB's Potiga (ezogabine) in the country. It says that Potiga is a drug that activates the potassium channel in adults with partial-onset...

  • Valeant Getting Its Sexy On With 'Female Viagra' Play. AMY REEVES // Investors Business Daily;8/21/2015, pA04 

    The article reports on the decision of Canadian specialty-drug maker Valeant Pharmaceuticals International Inc. to acquire pharmaceutical company Sprout Pharmaceuticals Inc. in 2015 after the U.S. Food and Drug Administration approved the latter's female aphrodisiac Addyi. It states that move...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics